Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The independent contribution of postprandial glucose (PPG) excursions to the overall glucose exposure and its role in the development of both micro- and macrovascular complications of diabetes remain subject to continuing debate in type 2 diabetes. Discussion continues on whether postprandial hyperglycemia is the main contributor to the overall hyperglycemia in fairly well-controlled individuals, whereas basal hyperglycemia becomes the preponderant contributor in poorly controlled patients. The concern about the role of PPG as a risk factor for diabetes complications is related to the controversial data obtained in individuals with impaired glucose tolerance. It remains, however, that the total glucose exposure as reflected by hemoglobin A1c (HbA1c) levels is an undoubted major vascular risk factor. Excluding the contribution of PPG is nonsensical. In support of this position is the fact that the absolute impact of PPG on HbA1c, expressed as percentage levels of HbA1c, remains constant at 1% across the HbA1c continuum in non-insulin-treated type 2 diabetes patients. This key feature clearly depicts the absolute contribution of PPG in contrast to its relative contribution and better explains why PPG contributes to the excess of glycation with the basal hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Self-citation(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310 · cited 1×
“Even though it has been demonstrated that the oxidative stress is activated during glycemic excursions (e.g., post-prandial states 12,62,63 ), some diabetologists continue to question the possible deleterious effects of both glucose variability and postprandial hyperglycemia.”
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Hanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., & Trovati, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1005 · Cited by 569
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 2×
“36,37 The discrepancies between the duration of physiological versus pathophysiological PPG excursions raise questions as to which method should be used for assessing PPG increments.”
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Esposito, K., Giugliano, D., Nappo, F., & Marfella, R. (2004) · Circulation · doi:10.1161/01.cir.0000134501.57864.66 · Cited by 440 · cited 1×
“21 Even in persons with impaired glucose tolerance, two drugs both aimed at reducing PPG excursions achieve different cardiovascular outcomes (i.e., acarbose appears to reduce the incidence of events, 18 whereas nateglinide does not 20 ).”
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409
Avignon, A., Radauceanu, A., & Monnier, L. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1822 · Cited by 363
Self-citationRaz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351
Carbohydrate Metabolism in Non-Insulin-Dependent Diabetes Mellitus
Dinneen, S., Gerich, J., & Rizza, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271007 · Cited by 279
Role of Hyperglycemia in Nitrotyrosine Postprandial Generation
Ceriello, A., Quagliaro, L., Catone, B., Pascon, R., Piazzola, M., Bais, B., Marra, G., Tonutti, L., Taboga, C., & Motz, E. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1439 · Cited by 257
Bolli, G. B., & Gerich, J. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403223101203 · Cited by 235
Plasma Glucose Levels Throughout the Day and HbA1c Interrelationships in Type 2 Diabetes
Bonora, E., Calcaterra, F., Lombardi, S., Bonfante, N., Formentini, G., Bonadonna, R. C., & Muggeo, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2023 · Cited by 235
Boden, G., Chen, X., & Urbain, J. L. (1996) · Diabetes · doi:10.2337/diab.45.8.1044 · Cited by 228 · cited 1×
“58 This deterioration was evident when HbA1c levels ranged from 7% to 8%.”
Bonora, E., Corrao, G., Bagnardi, V., Ceriello, A., Comaschi, M., Montanari, P., & Meigs, J. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0203-x · Cited by 141
Cited by
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“…2007 that using CGM in people with T2DM reveals critical abnormalities in glycaemic homeostasis, including the early-morning hormone-induced spikes in blood levels of glucose known as the dawn phenomenon, high postprandial glycaemic excursions and extensive short-term glycaemic variability 27–32 .”
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“[115] Therefore, in patients with T2DM, reducing FPG with basal insulin and targeting mealtime glucose excursions with a short-acting GLP-1 RA may be a logical option in the treatment of patients inadequately controlled with basal insulin.”
Background
Metadata
- Authors
- Monnier, L., Colette, C., & Owens, D.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2011-06
- Volume
- 13
- Issue
- S1
- Pages
- S-25-S-32
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2019750598
- Cited by
- 88
- References
- 29
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.